Patent ID: 8828939
Filing Date: 2014-09-09
Classification: A61P,C12N

Abstract:
1. A modified human Factor VII, human Factor Vila, or human Factor IX polypeptide having a lengthened activation domain amino acid sequence as compared to a corresponding unmodified, native human Factor VII, human Factor Vila, or human Factor IX, the modified polypeptide comprising (a) a human Factor VII, human Factor Vila, or human Factor IX polypeptide wherein all or a portion of an activation domain from human Factor IX, human Factor X, or human Prothrombin is inserted into the native activation domain of the human Factor VII, human Factor Vila, or human Factor IX polypeptide, such that the modified polypeptide has a lengthened activation domain amino acid sequence; or (b) a human Factor VII, human Factor Vila, or human Factor IX polypeptide wherein all or a portion of the native activation domain is removed and all or a portion of an activation domain from human Factor IX, human Factor X, or human Prothrombin is inserted, such that the modified polypeptide has a lengthened activation domain amino acid sequence; wherein the modified human Factor VII, human Factor Vila, or human Factor IX polypeptide is modified only in the activation domain and has an increased half-life as compared to the unmodified, native human Factor VII, human Factor Vila, or human Factor IX.